LENZ Therapeutics (LENZ) Competitors

LENZ Therapeutics logo
$3.82 -0.31 (-7.51%)
Closing price 04:00 PM Eastern
Extended Trading
$3.87 +0.05 (+1.31%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LENZ vs. GYRE, RLMD, EOLS, PHAT, and AQST

Should you buy LENZ Therapeutics stock or one of its competitors? LENZ Therapeutics's main competitors and comparable companies include Gyre Therapeutics (GYRE), Relmada Therapeutics (RLMD), Evolus (EOLS), Phathom Pharmaceuticals (PHAT), and Aquestive Therapeutics (AQST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LENZ Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

LENZ Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 257.14%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Gyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Gyre Therapeutics has a net margin of -14.80% compared to LENZ Therapeutics' net margin of -1,134.97%. Gyre Therapeutics' return on equity of -7.39% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gyre Therapeutics-14.80% -7.39% -5.74%
LENZ Therapeutics -1,134.97%-59.56%-54.75%

Gyre Therapeutics has higher revenue and earnings than LENZ Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gyre Therapeutics$116.59M4.26$5.03M-$0.20N/A
LENZ Therapeutics$19.09M6.80-$82.13M-$4.49N/A

Gyre Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, LENZ Therapeutics had 2 more articles in the media than Gyre Therapeutics. MarketBeat recorded 4 mentions for LENZ Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.94 beat LENZ Therapeutics' score of 0.88 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gyre Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LENZ Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Gyre Therapeutics beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Relmada Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -1,134.97%. Relmada Therapeutics' return on equity of -37.25% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -37.25% -34.87%
LENZ Therapeutics -1,134.97%-59.56%-54.75%

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 185.04%. LENZ Therapeutics has a consensus target price of $14.75, indicating a potential upside of 257.14%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Relmada Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Relmada Therapeutics has higher earnings, but lower revenue than LENZ Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A
LENZ Therapeutics$19.09M6.80-$82.13M-$4.49N/A

In the previous week, Relmada Therapeutics had 7 more articles in the media than LENZ Therapeutics. MarketBeat recorded 11 mentions for Relmada Therapeutics and 4 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.88 beat Relmada Therapeutics' score of 0.46 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
LENZ Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Relmada Therapeutics beats LENZ Therapeutics on 10 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Evolus?

LENZ Therapeutics (NASDAQ:LENZ) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Evolus had 12 more articles in the media than LENZ Therapeutics. MarketBeat recorded 16 mentions for Evolus and 4 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.88 beat Evolus' score of 0.72 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evolus
3 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LENZ Therapeutics currently has a consensus price target of $14.75, indicating a potential upside of 257.14%. Evolus has a consensus price target of $15.00, indicating a potential upside of 115.52%. Given LENZ Therapeutics' higher probable upside, equities analysts plainly believe LENZ Therapeutics is more favorable than Evolus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Evolus
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Evolus has a net margin of -9.56% compared to LENZ Therapeutics' net margin of -1,134.97%. Evolus' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-1,134.97% -59.56% -54.75%
Evolus -9.56%N/A -11.10%

LENZ Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Evolus has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Evolus has higher revenue and earnings than LENZ Therapeutics. Evolus is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M6.80-$82.13M-$4.49N/A
Evolus$297.18M1.55-$51.64M-$0.47N/A

Summary

Evolus beats LENZ Therapeutics on 10 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, LENZ Therapeutics had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for LENZ Therapeutics and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.82 beat LENZ Therapeutics' score of 0.88 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Phathom Pharmaceuticals Very Positive
LENZ Therapeutics Positive

Phathom Pharmaceuticals currently has a consensus target price of $20.11, indicating a potential upside of 231.87%. LENZ Therapeutics has a consensus target price of $14.75, indicating a potential upside of 257.14%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Phathom Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phathom Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Phathom Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

LENZ Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom Pharmaceuticals$274.88M1.79-$221.25M-$1.03N/A
LENZ Therapeutics$19.09M6.80-$82.13M-$4.49N/A

Phathom Pharmaceuticals has a net margin of -30.19% compared to LENZ Therapeutics' net margin of -1,134.97%. Phathom Pharmaceuticals' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Phathom Pharmaceuticals-30.19% N/A -13.38%
LENZ Therapeutics -1,134.97%-59.56%-54.75%

Summary

Phathom Pharmaceuticals beats LENZ Therapeutics on 11 of the 17 factors compared between the two stocks.

How does LENZ Therapeutics compare to Aquestive Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Aquestive Therapeutics has a net margin of -162.33% compared to LENZ Therapeutics' net margin of -1,134.97%. Aquestive Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-1,134.97% -59.56% -54.75%
Aquestive Therapeutics -162.33%N/A -57.35%

LENZ Therapeutics has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M6.80-$82.13M-$4.49N/A
Aquestive Therapeutics$44.54M11.03-$83.78M-$0.64N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LENZ Therapeutics presently has a consensus price target of $14.75, indicating a potential upside of 257.14%. Aquestive Therapeutics has a consensus price target of $8.75, indicating a potential upside of 123.79%. Given LENZ Therapeutics' higher probable upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Aquestive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Aquestive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Aquestive Therapeutics had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for Aquestive Therapeutics and 4 mentions for LENZ Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.26 beat LENZ Therapeutics' score of 0.88 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aquestive Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LENZ Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Summary

Aquestive Therapeutics beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LENZ vs. The Competition

MetricLENZ TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$128.51M$13.76B$7.83B$11.75B
Dividend YieldN/A2.58%2.47%4.41%
P/E RatioN/A29.0734.3430.11
Price / Sales6.297.748.005.34
Price / CashN/A15.7421.0222.34
Price / Book0.635.194.763.85
Net Income-$82.13M$2.88B$3.52B$393.14M
7 Day Performance-10.96%-3.87%-5.34%-4.53%
1 Month Performance16.82%-3.96%-3.61%-5.86%
1 Year Performance-85.08%-7.13%0.01%-7.78%

LENZ Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LENZ
LENZ Therapeutics
3.6315 of 5 stars
$3.82
-7.5%
$14.75
+286.1%
-83.9%$128.51M$19.09MN/A152
GYRE
Gyre Therapeutics
0.6281 of 5 stars
$4.23
-9.0%
N/A-46.1%$471.69M$116.59MN/A618
RLMD
Relmada Therapeutics
3.0873 of 5 stars
$4.27
+3.1%
$12.00
+181.0%
+6.6%$455.48MN/AN/A17
EOLS
Evolus
3.27 of 5 stars
$6.81
-2.4%
$15.00
+120.3%
-3.6%$449.80M$297.18MN/A353
PHAT
Phathom Pharmaceuticals
3.7596 of 5 stars
$5.45
+2.3%
$20.11
+269.0%
-58.4%$443.03M$175.11MN/A371

Related Companies and Tools


This page (NASDAQ:LENZ) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners